Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISTH 2022 | Unmet needs in hemophilia: guidelines for emicizumab & better therapeutics for hemophilia A

Melissa Bou Jaoudeh • 11 Jul 2022
ISTH 2022
Hemophilia Antibodies Emicizumab

Melissa Bou Jaoudeh, PhD, Sorbonne University, Paris, France, discusses some of the current challenges in the field of hemophilia, explaining that it is important to define better guidelines about the use of emicizumab, as well as to develop more efficient therapeutics with extended half-lives for patients with hemophilia A. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Melissa Bou Jaoudeh

1:39
Therapeutic potential of IdeS in hemophilia A with inhibitors
Melissa Bou Jaoudeh • 11 Jul 2022
2:27
The impact of hemophilia inhibitors on patient outcomes
Melissa Bou Jaoudeh • 11 Jul 2022

Related Videos

1:08
The current landscape of hemophilia treatment: an update from ASH 2023
Glaivy Batsuli • 10 Dec 2023
1:18
Unmet needs in hemophilia treatment
Glaivy Batsuli • 10 Dec 2023
1:11
Improving outcomes for hemophilia patients through the implementation of gene therapies
Evelien Krumb • 12 Dec 2023
1:27
The impact of emicizumab on the hemophilia treatment landscape
Glaivy Batsuli • 10 Dec 2023
The content of VJHemOnc is intended for healthcare professionals